title: Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice.
abstract: Although numerous transgenic mouse models for atherosclerosis have been developed recently, little is known about their response to hypolipidaemic or anti-atherosclerotic agents. We investigated the effect of the known hypocholesterolaemic and anti-atherosclerotic drug probucol on serum lipids, lipoproteins and atherosclerosis in fat-fed low density lipoprotein (LDL) receptor deficient mice. Probucol at doses of 0.2 and 1% in the diet which are similar to those used in the mouse by other investigators reduced serum cholesterol by 26 and 37%, respectively. Probucol also reduced serum triglyceride levels by 33 and 47% at doses of 0.2 and 1%, respectively. The decrease in serum cholesterol and triglycerides was mainly due to a decrease of these lipids in VLDL and or chylomicrons. Despite these potentially beneficial changes in serum lipids atherosclerotic lesion areas in the aortic root were unchanged in the probucol treated mice. After 12 weeks treatment most of the mice receiving probucol had swollen feet and tails due to oedema. Histological examination of the base of the hearts from the probucol treated mice revealed lipid droplets within the reticuloendothelial and other interstitial cells. There was also an interstitial subacute inflammatory cell infiltration associated with the lipid deposition. The oedema induced by probucol could be the result of cardiac insufficiency due to interstitial lipidosis and inflammation in the base of the heart together with the extensive atherosclerotic lesions in the aortic sinus.
authors.affiliation: Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, NFSP(North), Harlow, Essex, UK. g_martin_benson@sbphrd.com
authors.forename: G M
authors.initials: GM
authors.lastname: Benson
authors.forename: R
authors.initials: R
authors.lastname: Schiffelers
authors.forename: C
authors.initials: C
authors.lastname: Nicols
authors.forename: J
authors.initials: J
authors.lastname: Latcham
authors.forename: M
authors.initials: M
authors.lastname: Vidgeon-Hart
authors.forename: C D
authors.initials: CD
authors.lastname: Toseland
authors.forename: K E
authors.initials: KE
authors.lastname: Suckling
authors.forename: P H
authors.initials: PH
authors.lastname: Groot
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000633:toxicity; D001011:Aorta / Q000473:pathology; D001161:Arteriosclerosis / Q000473:pathology*; D002784:Cholesterol / Q000097:blood; D004041:Dietary Fats / Q000008:administration & dosage*; D005260:Female; D008055:Lipids / Q000097:blood*; D051379:Mice; D011341:Probucol / Q000494:pharmacology* / Q000633:toxicity; D011973:Receptors, LDL / Q000172:deficiency*; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D004041:Dietary Fats; D008055:Lipids; D011973:Receptors, LDL; D014280:Triglycerides; D002784:Cholesterol; D011341:Probucol